Acurx Pharmaceuticals, Inc. (ACXP): Total Liabilities
$2.42M
As of 2025-12-31
$2.83M
As of 2026-06-30
+5.5%
3-year compound annual growth
+35.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.42M | -25.3% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $3.24M | +6.6% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $3.04M | +47.6% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $2.06M | +144.3% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $843.9K | +61.5% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $522.4K | n/a | 2022-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $2.42M | -25.3% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $1.30M | -45.3% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $1.45M | +74.2% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $11.38M | +12.4% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $2.24M | +45.9% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $1.64M | -16.8% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $4.57M | +106.0% |
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $1.43M | +109.7% |
| GT Biopharma, Inc. (GTBP) | 2025-09-30 | $1.32M | n/a |
Compare ACXP, SILO, RKTO, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗